The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 1, 2002, Pages 30-38

  Markowitz, John S ^a,b   DeVane, C Lindsay ^a   Liston, Heidi L ^a   Boulton, David W ^a   Risch, S Craig ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; GLUTATHIONE; GLYCINE; NEUROLEPTIC AGENT; OLANZAPINE; PROBENECID; RISPERIDONE;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG OXIDATION; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METHYLATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BENZODIAZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; PIRENZEPINE; PROBENECID; RENAL AGENTS; RISPERIDONE;

EID: 0036163846     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.119815     Document Type: Article

References (27)

1. Atypical antipsychotics. I. Pharmacology, pharmacokinetics, and efficacy
2. Therapeutic drug monitoring: Principles and practice
3. Clozapine plasma level monitoring: Current status
4. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients
5. Drugs as substrates of metabolic enzymes: Antipsychotics
6. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
7. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients
8. Clozapine disposition covaries with CYP1A2 activity determined by the caffeine test
9. Disposition of clozapine in man: Lack of an association with debrisoquine and S-mephenytoin hydroxylation polymorphisms
10. Cytochrome P4502D6 does not determine response to clozapine
11. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
12. Disposition and biotransformation of the antipsychotic agent olanzapine in humans
13. An evaluation of risperidone drug interactions
14. Olanzapine: Pharmacokinetic and pharmacodynamic profile
15. Probenecid impairment of acetaminophen and lorazepam clearance: Direct inhibition of ether glucuronide formation
16. Drug glucuronidation in clinical psychopharmacology
17. A high performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine
18. Olanzapine 10-N-glucuronide-A tertiary N-glucuronide unique to humans
19. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein
20. Expressed human UGTI.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides
21. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: Can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?
22. Human recombinant P-glycoprotein specificity for antipsychotics
23. Drug glucuronidation in humans
24. Glucuronidation of drugs: A reevaluation of the pharmacological significance of the conjugates and modulating factors
25. Human liver morphine UDP-glucuronyltransferase enantioselectivity and inhibition by opioid congeners and oxazepam
26. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam